5 blue chip ASX 200 shares to buy in October and hold for 10 years

Let's see why these shares could be great long term options according to analysts.

| More on:
Two smiling work colleagues discuss an investment at their office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Analysts identify five ASX 200 blue-chip shares as top long-term picks due to their robust growth potential and strategic market positions.
  • These shares are involved in sectors such as gaming technology, biotechnology, property, and digital platforms, each capitalising on global trends.
  • The companies are expected to deliver sustained earnings growth, supported by strong balance sheets and strategic expansions.

The S&P/ASX 200 index has started the new quarter just shy of record highs.

But that doesn't mean there aren't any blue-chip opportunities out there for investors.

For example, five ASX 200 blue chip shares that analysts think are in the buy zone in October are listed below. Here's why they could be top long-term picks:

Aristocrat Leisure Ltd (ASX: ALL)

Gaming technology powerhouse Aristocrat Leisure has expanded successfully beyond poker machines in recent years. For example, its acquisition of NeoGames has boosted exposure to the fast-growing real money gaming and online lottery sector. With strong earnings growth expected and resilient cash flow generation, Aristocrat remains a very attractive ASX 200 blue chip share.

Bell Potter is a fan and has a buy rating and $79.00 price target on its shares.

Cochlear Ltd (ASX: COH)

Hearing implant leader Cochlear could be a great buy and hold option. Demand for its devices is rising on the back of ageing populations across the globe and broader access to hearing healthcare. With a robust balance sheet and a track record of delivering both growth and dividends, Cochlear continues to earn its place as a reliable blue-chip holding.

UBS currently rates Cochlear as a buy with a $350.00 price target.

CSL Ltd (ASX: CSL)

Biotech leader CSL has faced pressure in recent months, with investor sentiment hit by the planned spin-off of Seqirus and potential US tariffs on pharmaceutical products. Even so, major brokers remain upbeat, with price targets significantly higher than current levels. And with plasma demand growing, new therapies in the pipeline, and a heavy investment in US manufacturing to reduce risk, CSL continues to stand out as a core long-term holding. Especially while it trades near a 52-week low.

Morgans currently has a buy rating and $293.83 price target on its shares.

Goodman Group (ASX: GMG)

Property giant Goodman Group has capitalised on surging demand for logistics and data centre space. With e-commerce, cloud computing, and AI infrastructure all requiring new developments, Goodman's global pipeline positions it at the heart of these megatrends. Backed by a strong balance sheet and disciplined capital management, this ASX 200 blue chip share looks well-placed to deliver sustained growth over the next decade.

Bell Potter is bullish and has a buy rating and $40.80 price target on its shares.

REA Group Ltd (ASX: REA)

Finally, REA Group has cemented itself as the go-to digital property platform in Australia. Pricing power, growth in adjacent services, and expansion offshore have helped it sustain double-digit earnings growth. And with the housing market expected to boom as interest rates fall, the coming years look likely to be very positive.

Bell Potter is also bullish on this one. It has a buy rating and $284.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, Goodman Group, and REA Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and Goodman Group. The Motley Fool Australia has recommended CSL, Cochlear, and Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Blue Chip Shares

3 ASX blue-chip shares I'd buy with $3,000 right now

These big stocks have a strong market position. Here’s why they’re buys…

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Blue Chip Shares

3 high-quality ASX 200 shares now trading at multi-year discounts

These shares could be dirt cheap according to analysts.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Blue Chip Shares

Where to invest $10,000 in ASX shares in December

These shares could be great picks for Aussie investors this month.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

These are the top ASX blue-chip shares I'd buy today

I believe these large stocks still have significant growth potential.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Blue Chip Shares

3 ASX stocks I'd trust with $10,000 for the next decade

Let's see why these blue chips could be great long term picks for investors.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Blue Chip Shares

These top ASX 200 stocks could rise 25% to 60%

These shares could be cheap at current levels according to analysts.

Read more »

Two brokers analysing stocks.
Blue Chip Shares

Why are QBE shares sinking 6% today?

Let's see how the insurance giant is performing in FY 2025.

Read more »

A group of businesspeople clapping.
Blue Chip Shares

My best ASX stocks to invest $2,000 in right now

Brokers sees significant value in these beaten down stocks.

Read more »